98063-21-9Relevant academic research and scientific papers
INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER
-
Page/Page column 79, (2008/12/07)
A CPT inhibitor compound is represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof: or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject having cancer comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid
-
, (2008/06/13)
R or S aminocarnitine, R or S phosphonium aminocarnitine and R and S 3,4 diaminobutanoic acid, and their derivatives are prepared using starting from aspartic acid with the same configuration as the desired compounds. This process is advantageous from the industrial point of view in terms of the type of reactants used, the reduced volumes of solvents and the possibility of avoiding purification of the intermediate products.
Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid
-
, (2008/06/13)
A process is described for the preparation of R or S aminocarnitine, R or S phosphonium aminocarnitine and R and S 3,4 diaminobutanoic acid, and their derivatives with the following formula: 1where Y is as described in the attached description, starting from aspartic acid with the same configuration as the desired compounds. This process is advantageous from the industrial point of view in terms of the type of reactants used, the reduced volumes of solvents and the possibility of avoiding purification of the intermediate products.
Synthesis of (R) and (S)-aminocarnitine, (R) and (S)-4-phosphonium-3-amino-butanoate, (R) and (S) 3,4-diaminobutanoic acid, and their derivatives starting from D- and L-aspartic acid
-
, (2008/06/13)
A process is described for the preparation of R or S aminocarnitine, R or S phosphonium aminocarnitine and R and S 3,4 diaminobutanoic acid, and their derivatives with the following formula: where Y is as described in the attached description, starting from aspartic acid with the same configuration as the desired compounds. This process is advantageous from the industrial point of view in terms of the type of reactants used, the reduced volumes of solvents and the possibility of avoiding purification of the intermediate products.
A Practical and Stereoconservative Synthesis of (R)-3-Amino-4-(trimethyl-ammonio)butanoate [(R)-Aminocarnitine], and Its Trimethylphosphonium and Simple Ammonium Analogues Starting from D-Aspartic Acid
Calvisi, Giuseppina,Dell'Uomo, Natalina,De Angelis, Francesco,Dejas, Roberto,Giannessi, Fabio,Tinti, Maria Ornella
, p. 4501 - 4505 (2007/10/03)
We have developed a new stereospecific synthesis of (R)-aminocarnitine using D-aspartic acid as the starting material. This strategy, which is simple and amenable to an industrial scale-up, gives the target compound in six steps and in fairly good overall
Synthesis of (R) and (S) -aminocarnitine and their derivatives starting from D- and L-aspartic acid
-
, (2008/06/13)
R or S aminocarnitine and their derivatives with formula (I) where Y is as described in the description, starting with aspartic acid with the same configuration as the aminocarnitine desired. This process has advantage in the type of reactants used, reduced volumes of solvents and the possibility of avoiding purification of intermediate products.
Process for producing R-aminocarnitine and S-aminocarnitine
-
, (2008/06/13)
A process for producing aminocarnitine is described, wherein methanesulfonylcarnitine is converted to a lactone which is reacted with an azide to give azidocarnitine. The catalytic hydrogenation of azidocarnitine gives aminocarnitine.
The β-Lactone Route to a Totally Stereoselective Synthesis of Carnitine Derivatives
Bernabei, Ida,Castagnani, Roberto,Angelis, Francesco De,Fusco, Enrico De,Gianessi, Fabio,et al.
, p. 826 - 831 (2007/10/03)
The syntheses of the enantiomerically pure, carnitine-related β-lactones 10 and 12 starting from various carnitine precursors of opposite configuration (or carnitine itself) are described. (R)-3-Chlorocarnitine (20) has also been directly prepared from (S)-carnitine (14) and has been cyclized to 12 by a second inversion of configuration of the stereogenic centre.By nucleophilic attack at the carbonyl carbon, the β-lactone carnitine derivatives have been converted into esters, amides, and guanidino congeners.Following this route, it is possible to obtain the biologically active isomer (R)-carnitine (1) starting from the otherwise useless industrial by-product (S)-carnitine (14).Nucleophilic attack by selected ambident nucleophiles at the β-carbon of the same β-lactone derivatives results in a second inversion of configuration of the stereogenic centre.Besides aminocarnitine (3), chiral acetylcarnitine (2) and acetylthiocarnitine (5) have been synthesized in homochiral forms following this latter procedure. - Keywords: asymmetric ring-opening; carnitine; cyclizations; β-lactones; nucleophilic substitutions
Process for producing R-aminicarnitine and S-aminocarnitine
-
, (2008/06/13)
A process for producing aminocarnitine is described, wherein methanesulfonylcarnitine is converted to a lactone which is reacted with an azide to give azidocarnitine. The catalytic hydrogenation of azidocarnitine gives aminocarnitine.
